1.辽宁省药品检验检测院/国家药品监督管理局化学药品质量研究与评价重点实验室,沈阳 110036
2.辽宁省检验检测认证中心,沈阳 110036
Received:10 January 2023,
Revised:2023-06-12,
Accepted:12 June 2023,
Published:15 August 2023
移动端阅览
李尚颖,岳青阳,张耀文,等.GC-MS/MS法同时测定氯沙坦钾原料药及其制剂中6种N-亚硝胺类基因毒性杂质[J].中国药房,2023,34(15):1830-1834.
LI Shangying,YUE Qingyang,ZHANG Yaowen,et al.Simultaneous determination of 6 kinds of N-nitrosamines genotoxic impurities in losartan potassium raw material and its formulations by GC-MS/MS[J].ZHONGGUO YAOFANG,2023,34(15):1830-1834.
李尚颖,岳青阳,张耀文,等.GC-MS/MS法同时测定氯沙坦钾原料药及其制剂中6种N-亚硝胺类基因毒性杂质[J].中国药房,2023,34(15):1830-1834. DOI: 10.6039/j.issn.1001-0408.2023.15.08.
LI Shangying,YUE Qingyang,ZHANG Yaowen,et al.Simultaneous determination of 6 kinds of N-nitrosamines genotoxic impurities in losartan potassium raw material and its formulations by GC-MS/MS[J].ZHONGGUO YAOFANG,2023,34(15):1830-1834. DOI: 10.6039/j.issn.1001-0408.2023.15.08.
目的
2
建立同时测定氯沙坦钾原料药及其制剂中6种
N
-亚硝胺类基因毒性杂质含量的方法。
方法
2
采用气相色谱-串联质谱(GC-MS/MS)法测定氯沙坦钾原料药、氯沙坦钾片、氯沙坦钾胶囊、氯沙坦钾氢氯噻嗪片中
N
-亚硝基二甲胺(NDMA)、
N
-亚硝基二乙胺(NDEA)、
N
-亚硝基-
N
-乙基异丙胺(NEiPA)、
N
-亚硝基二异丙胺(NDiPA)、
N
-亚硝基二苯胺(NDPA)、
N
-亚硝基二丁胺(NDBA)6种
N
-亚硝胺类基因毒性杂质含量。色谱柱为SHIMADZU SH-L-17Sil MS毛细管柱;采用程序升温;进样口温度为250 ℃;进样量为1 μL;载气为氦气,流速为1 mL/min。离子源为电子轰击源,离子源温度为250 ℃;溶剂延迟时间为3.1 min;采集模式为多反应监测模式。
结果
2
NDMA、NDEA、NEiPA、NDiPA、NDPA、NDBA与其相邻色谱峰之间的分离效果均良好,分离度均大于3.8;其线性范围分别为4.9~486.0
、4.9~488.5、4.5~451.5、6.8~683.5、5.2~525.0、5.2~520.0 ng/mL(
r
≥0.999 8),定量限分别为4.86、4.88、4.52、6.84、5.25、5.20 ng/mL,检测限分别为0.97、0.98、0.90、1.37、1.05、1.04 ng/mL,重复性试验的RSD为2.2%~5.6%(
n
=6),精密度试验的RSD为0.5%~1.4%(
n
=6),稳定性试验的RSD为1.5%~3.4%(
n
=5),低、中、高质量浓度回收率溶液的平均加样回收率为83.4%~103.0%(RSD为1.2%~6.3%,
n
=3)。在氯沙坦钾原料药及其制剂中均未检出6种
N
-亚硝胺类基因毒性杂质。
结论
2
该法分离效果好、准确性高、灵敏、简便,可用于氯沙坦钾原料药及其制剂中6种
N
-亚硝胺类基因毒性杂质的检测。
OBJECTIVE
2
To establish a method for simultaneous determination of the contents of 6 kinds of
N
-nitrosamines genotoxic impurities in losartan potassium raw material and its formulations.
METHODS
2
GC-MS/MS was adopted to determine 6 kinds of
N
-nitrosamines genotoxic impurities in losartan potassium raw material, Losartan potassium tablet, Losartan potassium capsule and Losartan potassium hydrochlorothiazide tablets, such as
N
-nitrosodimethylamine (NDMA),
N
-nitrosodiethylamine (NDEA),
N
-ethyl-
N
-nitroso-2-propanamine (NEiPA),
N
-nitrosodiisopropylamine (NDiPA),
N
-nitrosodipropylamine (NDPA) and
N
-nitrosodibutylamine (NDBA). The separation was performed on SHIMADZU SH-L-17Sil MS capillary column by temperature-programmed GC, with injector temperature of 250 ℃, sample size of 1 μL, carrier gas of helium, and carrier flow rate of 1 mL/min. Electron ionization and multiple reaction monitoring (MRM) data acquisition mode were used, with an ion source temperature of 250 ℃ and solvent delay time of 3.1 min.
RESULTS
2
The separation among NDMA, NDEA, NEiPA, NDiPA, NDPA, NDBA and adjacent chromatographic peaks was good, and the separation rate was higher than 3.8; the linear ranges of them were 4.9-486.0, 4
.9-488.5, 4.5-451.5, 6.8-683.5, 5.2-525.0 and 5.2-520.0 ng/mL(all
r
≥0.999 8). The limits of quantitation were 4.86, 4.88, 4.52, 6.84, 5.25 and 5.20 ng/mL; the limits of detection were 0.97, 0.98, 0.90, 1.37, 1.05 and 1.04 ng/mL. RSDs of repeatability tests were 2.2%-5.6%(
n
=6), those of precision tests were 0.5%-1.4%(
n
=6), and those of stability tests were 1.5%-3.4%(
n
=5), respectively. Average recoveries of low-, medium- and high-concentration solution were 83.4%- 103.0% (RSDs were 1.2%-6.3%,
n
=3), respectively. No one among the 6 kinds of
N-
nitrosamines genotoxic impurities was detected in both losartan potassium raw material and formulations.
CONCLUSIONS
2
The method is good in separation effect, highly accurate, sensitive and simple. It can be used in the determination of the 6 kinds of
N-
nitrosamines genotoxic impurities.
史立川 , 蒲旭峰 , 余永秀 , 等 . 氯沙坦钾片仿制药与原研药溶出曲线的相似性评价 [J ] . 中国药房 , 2017 , 28 ( 30 ): 4298 - 4301 .
WEBER M A . Clinical experience with the angiotensin Ⅱ receptor antagonist losartan:a preliminary report [J ] . Am J Hypertens , 1992 , 5 ( 12 Pt 2 ): 247S - 251S .
闫佳琳 , 张芸楠 , 韩嘉伦 , 等 . 氯沙坦对比其他血管紧张素受体拮抗剂对血尿酸水平影响的Meta分析 [J ] . 临床药物治疗杂志 , 2022 , 20 ( 3 ): 46 - 52 .
耿荣凯 . 氯沙坦钾片治疗原发性高血压的临床分析 [J ] . 现代养生 , 2016 , 16 ( 22 ): 147 .
廖腾火生 . 氯沙坦钾生产过程中亚硝胺类基因毒性杂质控制技术的产业化研究 [J ] . 中国化工贸易 , 2020 ( 9 ): 100 , 103 .
李彩霞 , 朱坤丹 , 何佳佳 , 等 . GC-MS法测定氯沙坦钾中痕量的N-亚硝基二甲胺和N-亚硝基二乙胺 [J ] . 华西药学杂志 , 2022 , 37 ( 4 ): 425 - 428 .
MILLS A L , ALEXANDER M . N-nitrosamine formation by cultures of several microorganisms [J ] . Appl Environ Microbiol , 1976 , 31 ( 6 ): 892 - 895 .
杨竹 , 杭太俊 , 郭晓迪 , 等 . N-亚硝胺类基因毒性杂质的研究进展 [J ] . 药学与临床研究 , 2020 , 28 ( 4 ): 270 - 274 .
国家药典委员会 . 关于缬沙坦国家标准修订稿的公示:第二次 [EB/OL ] . [ 2023-04-04 ] . https://www.chp.org.cn/ydw/upload/userfiles/20190102/14561546393538788.pdf https://www.chp.org.cn/ydw/upload/userfiles/20190102/14561546393538788.pdf .
FDA . GC/MS headspace method for detection of NDMA in valsartan drug substance and drug products [EB/OL ] . [ 2023-04-04 ] . https://www.fda.gov/media/115965/download https://www.fda.gov/media/115965/download .
FDA . Combine direct injection N-Nitrosodimethylamine (NDMA) and N-Nitrosodimethylamine (NDEA) impurity assay by GC/MS [EB/OL ] . [ 2023-04-04 ] . https://www.fda.gov/media/117807/download https://www.fda.gov/media/117807/download .
葛雨琦 , 叶晓霞 , 乐健 , 等 . 厄贝沙坦制剂中N-亚硝胺类基因毒性杂质的GC-MS/MS测定 [J ] . 中国医药工业杂志 , 2020 , 51 ( 6 ): 759 - 764 .
周刚 , 李鹏飞 , 高家敏 . GC-MS/MS法测定阿莫西林原料药中12种N-亚硝胺类基因毒性杂质 [J ] . 中国抗生素杂志 , 2021 , 46 ( 4 ): 291 - 296 .
刘博 , 张佟 , 黄露 , 等 . 液相-高分辨质谱技术测定盐酸二甲双胍缓释片中7种亚硝胺杂质的方法学研究 [J ] . 中国药物警戒 , 2021 , 18 ( 5 ): 454 - 458,468 .
徐艳梅 , 韩彬 , 郝丽娟 , 等 . 高效液相色谱-串联质谱法同时测定3种N-亚硝胺类基因毒性杂质 [J ] . 医药导报 , 2022 , 41 ( 11 ): 1672 - 1676 .
赵丽 , 师真 , 洪雪花 , 等 . 气相色谱-质谱法/MRM测定生活饮用水中N-二甲基亚硝胺(NDMA)的方法研究 [J ] . 湖北农业科学 , 2018 , 57 ( 7 ): 108 - 110,113 .
李俊 , 陈红波 , 王英瑛 , 等 . GC-MS测定坎地沙坦酯中微量的N-亚硝基二甲胺和N-亚硝基二乙胺 [J ] . 中国现代应用药学 , 2020 , 37 ( 13 ): 1615 - 1620 .
0
Views
82
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
